Exploring Platinum-Based Treatment Realities: What do Real-World Data Reveal for the Management of Endometrial Cancer in Brazil? – the ECHOS-B Retrospective Study

Real-world data on the treatment and outcomes of patients with endometrial cancer, particularly in Latin America, are limited. We herein present the findings of the Endometrial Cancer Health and Clinical Outcomes Study in Brazil (ECHOS-B), which evaluated the treatment patterns for patients with endometrial cancer. The ECHOS-B retrospective study evaluated data on administrative claims by privately insured women with endometrial cancer in Brazil, who had received first-line platinum-based therapy from January 1, 2015, to December 31, 2019. Treatment patterns, demographic characteristics, and clinical characteristics were described. Disease progression and survival after first-line platinum-based therapy were also assessed. Out of 1,078 patients, 70.0% (n = 755) were treated with first-line systemic therapy. Of these, 520 (68.9%) received first-line platinum-based therapy (mean age 61.0 ± 12.3 years), and 54.4% (411/755) received first-line carboplatin/paclitaxel, alone or in combination. The mean time until the administration of the first-line platinum-based therapy was 4.8 ± 6.3 months; the mean duration of the first-line therapy was 3.1 ± 2.5 months; and the mean time until the next treatment was of 9.4 ± 7.3 months. Progression occurred in 41.3% of the patients (n = 215/520), with a median time of 18.2 months. The adjusted 1- to 5-year cumulative risks of progression/death were 36.2%, 52.1%, 57.1%, 57.1%, and 59.8% respectively. The 1- to 5-year cumulative risks of death were 10.4%, 23.7%, 27.6%, 31.8%, and 35.4% respectively. First-line platinum-based therapy for endometrial cancer is frequently used in Brazil; however, high rates of progression were observed, occurring within 2 years. Treatments to prevent or delay progression are needed.